CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II

Allison Betof Warner; Jason J Luke

doi:10.1158/1078-0432.CCR-23-1333

CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II

Clin Cancer Res. 2023 Oct 2;29(19):3829-3831. doi: 10.1158/1078-0432.CCR-23-1333.

Authors

Allison Betof Warner^{1

2}, Jason J Luke³

Affiliations

¹ Stanford Cancer Institute, Palo Alto, California.
² Department of Medicine, Stanford University, Stanford, California.
³ Department of Medicine, UPMC Hillman Cancer Center and the University of Pittsburgh, Pittsburgh, Pennsylvania.

Abstract

In this CCR Translations, we discuss the potential for tumor-infiltrating lymphocyte therapy to overcome immune checkpoint inhibitor resistance through CD4+-mediated and MHC-II-dependent killing. Validating these results from human tumors has potential to improve the clinical application of adoptive cellular transfer in advanced cancers. See related article by Draghi et al., p. 3937.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

CD4-Positive T-Lymphocytes / immunology
Humans
Immunotherapy, Adoptive
Lymphocytes, Tumor-Infiltrating* / immunology
Melanoma*
Signal Transduction

Abstract

Publication types

MeSH terms

Grants and funding